Constantine Manthous, MD
Critical Care Medicine · New Britain, CTNPI 1780643759
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Novo Nordisk accounts for 67.0% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $254, more than ten times the $15 reported in 2019.
Across 47 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$522
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$61
- Inspire Medical Systems, Inc.$55
- Pfizer$40
- Lilly USA, LLC$31
- Lundbeck LLC$24
- plus $47 from 2 others
What the payments were for
- Food & beverage$779100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $522 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $61 |
| Inspire Medical Systems, Inc. | 1 | $55 |
| Pfizer | 3 | $40 |
| Lilly USA, LLC | 1 | $31 |
| Lundbeck LLC | 1 | $24 |
| GSK | 1 | $23 |
| Alkermes, Inc. | 1 | $23 |
How this compares
$779 in reported general payments places this provider in the 60th percentile of 51 critical care medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 95 | $100,951 |
| MounjaroTirzepatide | 70 | $82,651 |
| JardianceEmpagliflozin | 38 | $46,038 |
| OzempicSemaglutide | 37 | $34,900 |
| MyrbetriqMirabegron | 15 | $18,661 |
| FarxigaDapagliflozin Propanediol | 14 | $13,615 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,472 |
| Atorvastatin Calcium | 404 | $4,601 |
| Esomeprazole Magnesium | 20 | $3,243 |
| Losartan Potassium | 200 | $2,182 |
| Lisinopril | 247 | $2,150 |
| Midodrine Hcl | 19 | $1,910 |
| SynthroidLevothyroxine Sodium | 27 | $1,903 |
| ValacyclovirValacyclovir Hcl | 22 | $1,805 |
| Escitalopram Oxalate | 120 | $1,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $40 | $102,319107 claims |
| Lilly USA, LLCMounjaro | $31 | $82,65170 claims |
| Novo NordiskOzempic | $522 | $34,90037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 51 critical care medicine providers in Connecticut.
Other critical care medicine in New Britain
- Laura AndrewsNew Britain$16
- Richard SilvermanWaterbury$560K
- David HillWaterbury$193K
- Philip SimkovitzTrumbull$24K
- David KaufmanBridgeport$20K
- Roland El GhazalNew Haven$19K
- Robert McDonaldWaterbury$13K
- Akhil KhoslaNew Haven$12K
- Andrew NotarianniNew Haven$4K
- Ferdinando UrbanoWaterbury$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.